Primary Vaccine Failure After 1 Dose of Varicella Vaccine in Healthy Children

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2008 Apr 19

PMID 18419532

Citations 60

Authors

David E Michalik

Sharon P Steinberg

Philip S LaRussa

Kathryn M Edwards

Peter F Wright

Ann M Arvin

Haley A Gans

Anne A Gershon

Affiliations

Soon will be listed here.

Abstract

Universal immunization of young children with 1 dose of varicella vaccine was recommended in the United States in 1995, and it has significantly decreased the incidence of chickenpox. Outbreaks of varicella, however, are reported among vaccinated children. Although vaccine effectiveness has usually been 85%, rates as low as 44% have been observed. Whether this is from primary or secondary vaccine failure-or both-is unclear. We tested serum samples from 148 healthy children immunized against varicella in New York, Tennessee, and California to determine their seroconversion rates, before and after 1 dose of Merck/Oka varicella vaccine. The median age at vaccination was 12.5 months; postvaccination serum samples were obtained on average 4 months later. Serum was tested for antibodies against varicella-zoster virus (VZV) by use of the previously validated sensitive and specific fluorescent antibody to membrane antigen (FAMA) assay. Of 148 healthy child vaccinees, 113 (76%) seroconverted, and 24% had no detectable VZV FAMA antibodies. Our data contrast with reported seroconversion rates of 86%-96% by other VZV antibody tests and suggest that many cases of varicella in immunized children are due to primary vaccine failure. A second dose of varicella vaccine is expected to increase seroconversion rates and vaccine effectiveness.

Citing Articles

Evaluation of flow cytometry-based fluorescent antibody to membrane antigen test to measure the humoral immunity against the varicella-zoster virus.

Lim J, Kim Y, Hwang J, Lee K, Park H Heliyon. 2024; 10(16):e36614.

PMID: 39262946 PMC: 11388681. DOI: 10.1016/j.heliyon.2024.e36614.

Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.

Mo Z, Huang S, Qiu L, Li C, Yu X, Li M Lancet Reg Health West Pac. 2023; 34:100707.

PMID: 37283962 PMC: 10240365. DOI: 10.1016/j.lanwpc.2023.100707.

Vaccination against Varicella Zoster Virus Infection in Less Developed Regions of Guangdong, China: A Cross-Sectional Serosurveillance Study.

Chen H, Liang C, Huang X, Ruan Q, Li Z, Hu X Vaccines (Basel). 2023; 11(3).

PMID: 36992078 PMC: 10056728. DOI: 10.3390/vaccines11030494.

25 Years of Varicella Vaccination in the United States.

Marin M, Seward J, Gershon A J Infect Dis. 2022; 226(Suppl 4):S375-S379.

PMID: 36265845 PMC: 10310989. DOI: 10.1093/infdis/jiac251.

Long-Term Varicella Zoster Virus Immunity in Paediatric Liver Transplant Patients Can Be Achieved by Booster Vaccinations-A Single-Centre, Retrospective, Observational Analysis.

Laue T, Oms E, Ohlendorf J, Baumann U Children (Basel). 2022; 9(2).

PMID: 35204851 PMC: 8870030. DOI: 10.3390/children9020130.

References

Gershon A, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P . Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA. 1984; 252(3):355-62. DOI: 10.1001/jama.252.3.355. View

Gershon A, Raker R, Steinberg S, DRUSIN L . Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life. Pediatrics. 1976; 58(5):692-6. View

Provost P, Krah D, Kuter B, Morton D, Schofield T, Wasmuth E . Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991; 9(2):111-6. DOI: 10.1016/0264-410x(91)90266-9. View

Saiman L, LaRussa P, Steinberg S, Zhou J, Baron K, Whittier S . Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2001; 22(5):279-83. DOI: 10.1086/501900. View

Lopez A, Guris D, Zimmerman L, Gladden L, Moore T, Haselow D . One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics. 2006; 117(6):e1070-7. DOI: 10.1542/peds.2005-2085. View

Gershon A . Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis. 1995; 10:93-124. View

Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B . Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004; 23(2):132-7. DOI: 10.1097/01.inf.0000109287.97518.67. View

Williams V, Gershon A, Brunell P . Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis. 1974; 130(6):669-72. DOI: 10.1093/infdis/130.6.669. View

Haddad M, Hill M, Pavia A, Green C, Jumaan A, DE A . Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005; 115(6):1488-93. DOI: 10.1542/peds.2004-1826. View

10.

Seward J, Zhang J, Maupin T, Mascola L, Jumaan A . Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004; 292(6):704-8. DOI: 10.1001/jama.292.6.704. View

11.

Shinefield H, Black S, Staehle B, Matthews H, Adelman T, Ensor K . Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002; 21(6):555-61. DOI: 10.1097/00006454-200206000-00014. View

12.

Gershon A, Kalter Z, Steinberg S, Kuhns W . Detection of antibody to Varicella-Zoster virus by immune adherence hemagglutination. Proc Soc Exp Biol Med. 1976; 151(4):762-5. DOI: 10.3181/00379727-151-39302. View

13.

Chaves S, Gargiullo P, Zhang J, Civen R, Guris D, Mascola L . Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007; 356(11):1121-9. DOI: 10.1056/NEJMoa064040. View

14.

Vazquez M, LaRussa P, Gershon A, Niccolai L, Muehlenbein C, Steinberg S . Effectiveness over time of varicella vaccine. JAMA. 2004; 291(7):851-5. DOI: 10.1001/jama.291.7.851. View

15.

Li S, Chan I, Matthews H, Heyse J, Chan C, Kuter B . Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002; 21(4):337-42. DOI: 10.1097/00006454-200204000-00014. View

16.

Lieberman J, Williams W, Miller J, Black S, Shinefield H, Henderson F . The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006; 25(7):615-22. DOI: 10.1097/01.inf.0000220209.35074.0b. View

17.

Krah D, Cho I, Schofield T, Ellis R . Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine. 1997; 15(1):61-4. DOI: 10.1016/s0264-410x(96)00107-7. View

18.

Johnson C, Shurin P, Fattlar D, Rome L, Kumar M . Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics. 1988; 81(4):512-8. View

19.

Gershon A, Steinberg S, Gelb L . Clinical reinfection with varicella-zoster virus. J Infect Dis. 1984; 149(2):137-42. DOI: 10.1093/infdis/149.2.137. View

20.

Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T . Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974; 2(7892):1288-90. DOI: 10.1016/s0140-6736(74)90144-5. View